1.1. Purpose The European Society for Vascular Surgery (ESVS) has developed guidelines
for treating patients with acute limb ischaemia (ALI). The focus on the guidelines is on lower …

BIOTRONIK's First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter
vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularisation of …

Patients with widespread atherosclerosis such as peripheral artery disease (PAD) have a
high risk of cardiovascular and limb symptoms and complications, which affects their quality …

Background: Although cardiovascular rehabilitation (CR) is well accepted in general, CR-
attendance and delivery still considerably vary between the European countries. Moreover …

Peripheral artery disease (PAD) affects over 200 million people globally and is a cause of
significant morbidity, mortality, and disability due to limb loss. Although secondary …

Background: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events
and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and …

Background Underuse of guideline‐recommended therapy in peripheral artery disease
(PAD) in administrative and procedural databases has been described, but reports on …

BACKGROUND: The evolving clinical burden of limb loss secondary to diabetes and
peripheral artery disease remains poorly characterized. We sought to examine secular …

Objective The aim of this study was to evaluate the contemporary population based
incidence of acute lower limb ischaemia (ALI) and factors associated with major …

Objective Long-term progression of peripheral arterial disease (PAD) as initial manifestation
of atherosclerotic arterial disease is not well described. Cardiovascular (CV) risk was …